Transporting silence: Design of carriers for siRNA to angiogenic endothelium

Journal of Controlled Release

Volumn 109, Issue 1-3, 2005, Pages 5-14

  Schiffelers, Raymond M ^a   Mixson, Archibald J ^b   Ansari, Aslam M ^c   Fens, Marcel H A M ^a   Tang, Quingquan ^c   Zhou, Qin ^c   Xu, Jun ^c   Molema, Grietje ^d   Lu, Patrick Y ^c   Scaria, Puthupparampil V ^c   Storm, Gert ^a   Woodle, Martin C ^c  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c Intradigm Corporation   (United States)

^d UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Angiogenesis; Drug targeting; RNA interference; siRNA

Indexed keywords

BIODEGRADATION; DRUG PRODUCTS; ENZYME INHIBITION; ENZYMES; GENES; TUMORS;

ANGIOGENESIS; DRUG TARGETING; RNA INTERFERENCE; SIRNA;

RNA;

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; ANTISENSE OLIGODEOXYNUCLEOTIDE; ARGINYLGLYCYLASPARTIC ACID; DIOLEOYLPHOSPHATIDYLETHANOLAMINE; DRUG CARRIER; HISTIDYLLYSINE; LIPOSOME; MACROGOL; NANOPARTICLE; POLY(ETHYLENEIMINE); POLYMER; POLYPEPTIDE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; COMPLEX FORMATION; CONFERENCE PAPER; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DESIGN; DRUG TARGETING; DRUG TISSUE LEVEL; DRUG UPTAKE; GENE SILENCING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; RNA INTERFERENCE; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM;

ANGIOGENESIS INHIBITORS; ANIMALS; CELLS, CULTURED; DRUG DELIVERY SYSTEMS; FLOW CYTOMETRY; HUMANS; INDICATORS AND REAGENTS; MICE; MICE, INBRED BALB C; MICROSCOPY, FLUORESCENCE; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES; PEPTIDES; PHOSPHATIDYLETHANOLAMINES; POLYETHYLENE GLYCOLS; RNA, SMALL INTERFERING;

EID: 28444497388     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2005.05.018     Document Type: Conference Paper

References (36)

1. P. Carmeliet Angiogenesis in health and disease Nat. Med. 9 2003 653 660
2. Y. Cao Antiangiogenic cancer therapy Semin. Cancer Biol. 14 2004 139 145
3. M. Kirsch, G. Schackert, and P.M. Black Metastasis and angiogenesis Cancer Treat. Res. 117 2004 285 304
4. H.G. Augustin Translating angiogenesis research into the clinic: the challenges ahead Br. J. Radiol. 76 1 2003 S3 S10 (Spec. No.)
5. M. Ziche, S. Donnini, and L. Morbidelli Development of new drugs in angiogenesis Curr. Drug Targets 5 2004 485 493
6. A.W. Griffioen, and G. Molema Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation Pharmacol. Rev. 52 2000 237 268
7. X.W. Bian, J.H. Chen, X.F. Jiang, J.S. Bai, Q.L. Wang, and X. Zhang Angiogenesis as an immunopharmacologic target in inflammation and cancer Int. Immunopharmacol. 4 2004 1537 1547
8. R.O. Schlingemann Role of growth factors and the wound healing response in age-related macular degeneration Graefes Arch. Clin. Exp. Ophthalmol. 242 2004 91 101
9. J. Baselga, L. Gianni, C. Geyer, E.A. Perez, A. Riva, and C. Jackisch Future options with trastuzumab for primary systemic and adjuvant therapy Semin. Oncol. 31 5 Suppl 10 2004 51 57
10. Eyetech Study Group Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results Ophthalmology 110 2003 979 986
11. D. Ribatti The crucial role of vascular permeability factor/vascular endothelial growth factor in angiogenesis: a historical review Br. J. Haematol. 128 2005 303 309
12. T. Tammela, B. Enholm, K. Alitalo, and K. Paavonen The biology of vascular endothelial growth factors Cardiovasc. Res. 65 2005 550 563
13. P.Y. Lu, F.Y. Xie, and M.C. Woodle Modulation of angiogenesis with siRNA inhibitors for novel therapeutics Trends Mol. Med. 11 3 2005 Mar 104 113
14. R.M. Schiffelers, M.H. Fens, A.P. Janssen, G. Molema, G. Storm, Liposomal targeting of angiogenic vasculature, Curr. Drug Del. (in press).
15. R.J. Kok, A.J. Schraa, E.J. Bos, H.E. Moorlag, S.A. Asgeirsdottir, M. Everts, D.K. Meijer, and G. Molema Preparation and functional evaluation of RGD-modified proteins as alpha(v)beta(3) integrin directed therapeutics Bioconjug. Chem. 13 2002 128 135
16. A.P. Janssen, R.M. Schiffelers, T.L. ten Hagen, G.A. Koning, A.J. Schraa, R.J. Kok, G. Storm, and G. Molema Peptide-targeted PEG-liposomes in anti-angiogenic therapy Int. J. Pharm. 254 2003 55 58
17. A.J. Schraa, R.J. Kok, S.M. Botter, S. Withoff, D.K. Meijer, L.F. de Leij, and G. Molema RGD-modified anti-CD3 antibodies redirect cytolytic capacity of cytotoxic T-lymphocytes toward alphavbeta3-expressing endothelial cells Int. J. Cancer 112 2004 279 285
18. F. Pastorino, C. Brignole, D. Marimpietri, M. Cilli, C. Gambini, D. Ribatti, R. Longhi, T.M. Allen, A. Corti, and M. Ponzoni Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy Cancer Res. 63 2003 7400 7409
19. F. Ye, H.Z. Chen, X. Xie, D.F. Ye, W.G. Lu, and Z.M. Ding Vascular endothelial growth factor (VEGF) and ovarian carcinoma cell supernatant activate signal transducers and activators of transcription (STATs) via VEGF receptor-2 (KDR) in human hemopoietic progenitor cells Gynecol. Oncol. 94 2004 125 133
20. R.Z. Renno, Y. Terada, M.J. Haddadin, N.A. Michaud, E.S. Gragoudas, and J.W. Miller Selective photodynamic therapy by targeted verteporfin delivery to experimental choroidal neovascularization mediated by a homing peptide to vascular endothelial growth factor receptor-2 Arch. Ophthalmol. 122 2004 1002 1011
21. R. Binetruy-Tournaire, C. Demangel, B. Malavaud, R. Vassy, S. Rouyre, M. Kraemer, J. Plouet, C. Derbin, G. Perret, and J.C. Mazie Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis EMBO J. 19 2000 1525 1533
22. N. Maeda, Y. Takeuchi, M. Takada, Y. Sadzuka, Y. Namba, and N. Oku Anti-neovascular therapy by use of tumor neovasculature-targeted long-circulating liposome J. Control. Release 100 2004 41 52
23. N. Maeda, Y. Takeuchi, M. Takada, Y. Namba, and N. Oku Synthesis of angiogenesis-targeted peptide and hydrophobized polyethylene glycol conjugate Bioorg. Med. Chem. Lett. 14 2004 1015 1017
24. K. Huppi, S.E. Martin, and N.J. Caplen Defining and assaying RNAi in mammalian cells Mol. Cell 17 2005 1 10
25. D.A. Braasch, Z. Paroo, A. Constantinescu, G. Ren, O.K. Oz, R.P. Mason, and D.R. Corey Biodistribution of phosphodiester and phosphorothioate siRNA Bioorg. Med. Chem. Lett. 14 2004 1139 1143
26. R.M. Schiffelers, A. Ansari, J. Xu, Q. Zhou, Q. Tang, G. Storm, G. Molema, P.Y. Lu, P.V. Scaria, and M.C. Woodle Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle Nucleic Acids Res. 32 2004 e149
27. B. Kim, Q. Tang, P.S. Biswas, J. Xu, R.M. Schiffelers, F.Y. Xie, A.M. Ansari, P.V. Scaria, M.C. Woodle, P.Y. Lu, and B.T. Rouse Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal keratitis Am. J. Pathol. 165 2004 2177 2185
28. Q.X. Leng, P. Scaria, J. Zhu, A.J. Mixson, Highly branched HK peptides are effective carriers of siRNA, J. Gene Med. (in press).
29. L. Zhang, N. Ambulos, and A.J. Mixson DNA delivery to cells in culture using peptides Methods Mol. Biol. 245 2004 33 52
30. B. Hanss, E. Leal-Pinto, L.A. Bruggeman, T.D. Copeland, and P.E. Klotman Identification and characterization of a cell membrane nucleic acid channel Proc. Natl. Acad. Sci. U. S. A. 95 1998 1921 1926
31. B. Kühnast, F. Dollé, S. Terrazzino, B. Rousseau, C. Loch, F. Vaufrey, F. Hinnen, I. Doignon, F. Pillon, C. David, C. Crouzel, and B. Tavitian General method to label antisense oligonucleotides with radioactive halogens for pharmacological and imaging studies Bioconjug. Chem. 11 2000 627 636
32. S. Filleur, A. Courtin, S. Ait-Si-Ali, J. Guglielmi, C. Merle, A. Harel-Bellan, P. Clezardin, and F. Cabon siRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 Can. Res. 63 2003 3919 3922
33. J.D. Heidel, S. Hu, X.F. Liu, T.J. Triche, and M.E. Davis Lack of interferon response in animals to naked siRNAs Nat. Biotechnol. 22 2004 1579 1582
34. S. Agrawal, and E.R. Kandimalla Antisense and siRNA as agonists of toll-like receptors Nat. Biotech. 22 2004 1533 1537
35. J. Woolard, W.Y. Wang, H.S. Bevan, Y. Qiu, L. Morbidelli, R.O. Pritchard-Jones, T.G. Cui, M. Sugiono, E. Waine, R. Perrin, R. Foster, J. Digby-Bell, J.D. Shields, C.E. Whittles, R.E. Mushens, D.A. Gillatt, M. Ziche, S.J. Harper, and D.O. Bates VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression Cancer Res. 64 2004 7822 7835
36. J. Grunstein, J.J. Masbad, R. Hickey, F. Giordano, and R.S. Johnson Isoforms of vascular endothelial growth factor act in a coordinate fashion to recruit and expand tumor vasculature Mol. Cell. Biol. 20 2000 7282 7291